Company Profile
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company provides the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte.
Its portfolio also includes Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis, JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors, JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors, and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors.
Its portfolio also includes JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC, JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer, JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma, and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis, as well as TUOYI/LOQTORZI/ZYTORVI for tumors.
Its portfolio also includes JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease, VV116/JT001, an oral nucleoside analog drug, and JUNSHIDA to treat hyperlipidemia. Founded in 2012, the company is headquartered in Shanghai, People's Republic of China.